

## Highlights of This Issue 1

### REVIEWS

- 3 | **TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies**  
Christian T. Hellwig and Markus Rehm
- 14 | **Oncogenic Viruses and Tumor Glucose Metabolism: Like Kids in a Candy Store**  
Evan Noch and Kamel Khalili

### THERAPEUTIC DISCOVERY

- 24 | **MUC13 Mucin Augments Pancreatic Tumorigenesis**  
Subhash C. Chauhan, Mara C. Ebeling, Diane M. Maher, Michael D. Koch, Akira Watanabe, Hiroyuki Aburatani, Yuhlong Lio, and Meena Jaggi
- 34 | **A 71-Gene Signature of TRAIL Sensitivity in Cancer Cells**  
Jun-Jie Chen, Steen Knudsen, Wiktor Mazin, Jesper Dahlgaard, and Baolin Zhang
- 45 | **Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells**  
Yan Liu, Shi-Yong Sun, Taofeek K. Owonikoko, Gabriel L. Sica, Walter J. Curran, Fadlo R. Khuri, and Xingming Deng
- 57 | **Effective Targeting of Hedgehog Signaling in a Medulloblastoma Model with PF-5274857, a Potent and Selective Smoothed Antagonist That Penetrates the Blood-Brain Barrier**  
Allison Rohner, Mary E. Spilker, Justine L. Lam, Bernadette Pascual, Darian Bartkowski, Qing John Li, Amy H. Yang, Greg Stevens, Meirong Xu, Peter A. Wells, Simon Planken, Sajiv Nair, and Shaoxian Sun
- 66 | **Genomic c-Myc Quadruplex DNA Selectively Kills Leukemia**  
Kara C. Sedoris, Shelia D. Thomas, Cortney R. Clarkson, David Muench, Ashraful Islam, Rajesh Singh, and Donald M. Miller

- 77 | **A Monoclonal Antibody against Human Notch1 Ligand-Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem-like Cells**  
Ankur Sharma, Anurag N. Paranjape, Annapoorni Rangarajan, and Rajan R. Dighe
- 87 | **SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-Resistant Growth of Prostate Cancer**  
Rusha Thomas and Nima Sharifi
- 98 | **Targeted Mutations in the ATR Pathway Define Agent-Specific Requirements for Cancer Cell Growth and Survival**  
Deborah Wilsker, Jon H. Chung, Ivan Pradilla, Eva Petermann, Thomas Helleday, and Fred Bunz
- 108 | **Aryl Hydrocarbon Receptor Agonists Induce MicroRNA-335 Expression and Inhibit Lung Metastasis of Estrogen Receptor Negative Breast Cancer Cells**  
Shu Zhang, KyoungHyun Kim, Un Ho Jin, Catherine Pfent, Huojun Cao, Brad Amendt, Xinyi Liu, Heather Wilson-Robles, and Stephen Safe

### PRECLINICAL DEVELOPMENT

- 119 | **A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer**  
Wendy L. Allen, Leanne Stevenson, Vicky M. Coyle, Puthen V. Jithesh, Irina Proutski, Gail Carson, Michael A. Gordon, Heinz-Josef D. Lenz, Sandra Van Schaeybroeck, Daniel B. Longley, and Patrick G. Johnston
- 132 | **Apigenin Induces Apoptosis in Human Leukemia Cells and Exhibits Anti-Leukemic Activity *In Vivo***  
Amit Budhraj, Ning Gao, Zhuo Zhang, Young-Ok Son, Senping Cheng, Xin Wang, Songze Ding, Andrew Hitron, Gang Chen, Jia Luo, and Xianglin Shi

- 143 **Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity**  
Yu Cao, James D. Marks, Qian Huang, Stephen I. Rudnick, Chiyi Xiong, Walter N. Hittelman, Xiaoxia Wen, John W. Marks, Lawrence H. Cheung, Kim Boland, Chun Li, Gregory P. Adams, and Michael G. Rosenblum
- 154 **MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis**  
Yan Cheng, Yi Zhang, Li Zhang, Xingcong Ren, Kathryn J. Huber-Keener, Xiaoyuan Liu, Lei Zhou, Jason Liao, Heike Keihack, Li Yan, Eric Rubin, and Jin-Ming Yang
- 165 **A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothed Antagonists**  
Venugopal Chenna, Chaoxin Hu, Dipankar Pramanik, Blake T. Aftab, Collins Karikari, Nathaniel R. Campbell, Seung-Mo Hong, Ming Zhao, Michelle A. Rudek, Saeed R. Khan, Charles M. Rudin, and Anirban Maitra
- 174 **MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells**  
Jenny M. Kreaehling, Jennifer Y. Gemmer, Damon Reed, Douglas Letson, Marilyn Bui, and Soner Altioek
- 183 **Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway**  
Ana Markovic, Karen L. MacKenzie, and Richard B. Lock
- 194 ***In Silico* Screening Reveals Structurally Diverse, Nanomolar Inhibitors of NQO2 That Are Functionally Active in Cells and Can Modulate NF- $\kappa$ B Signaling**  
Karen A. Nolan, Mark S. Dunstan, Mary C. Caraher, Katherine A. Scott, David Leys, and Ian J. Stratford
- 204 **Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin**  
Kunio Okamoto, Isamu Okamoto, Erina Hatashita, Kiyoko Kuwata, Haruka Yamaguchi, Aya Kita, Kentaro Yamanaka, Mayumi Ono, and Kazuhiko Nakagawa
- 214 **Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown**  
Sara Previdi, Giovanni Abbadessa, Francesca Dalò, Dennis S. France, and Massimo Broggin
- 224 **Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies**  
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, and David M. Goldenberg
- 235 **Targeting Interleukin-4 Receptor  $\alpha$  with Hybrid Peptide for Effective Cancer Therapy**  
Liyang Yang, Tomohisa Horibe, Masayuki Kohno, Mari Haramoto, Koji Ohara, Raj K. Puri, and Koji Kawakami


## MOLECULAR MEDICINE IN PRACTICE

- 244 **Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4**  
Koji Ueno, Hiroshi Hirata, Shahana Majid, Soichiro Yamamura, Varahram Shahryari, Z. Laura Tabatabai, Yuji Hinoda, and Rajvir Dahiya

---

## ABOUT THE COVER

Pancreatic cancer is extremely lethal, partially due to the aggressive nature of the disease and the lack of reliable markers for early detection. Mucin 13 (MUC13) was found to be overexpressed in pancreatic cancer tissue samples. In *in vitro* studies, the expression of MUC13 increased the oncogenic characteristics of pancreatic cancer cells, including increased cell proliferation, invasion, and modulation of tumorigenic signaling pathways. Exogenous MUC13 expression also increased tumorigenesis in a mouse model of pancreatic cancer. For details, see article by Chauhan and colleagues on page 24.



# Molecular Cancer Therapeutics

**11 (1)**

*Mol Cancer Ther* 2012;11:1-253.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/11/1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/11/1>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.